Silexan

Phase 3Small molecule

DDeakin University

Silexan is one of 56 small molecule programs targeting Post-Traumatic Stress Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Post-Traumatic Stress DisorderRecruiting

Post-Traumatic Stress DisorderPhase 3

Recruiting

Competition

Competitive Landscape

61 competitors in Post-Traumatic Stress Disorder

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Approved

5 2

Minipress

Pfizer

Approved

4 3

Epidiolex

Jazz Pharmaceuticals

Approved

2 4

Namenda

AbbVie

Approved

1 5

Marinol

Jazz Pharmaceuticals

Approved

1 6

Ritalin

Novartis

Approved

1 7

Revia

Teva

Approved

1 8

Zoloft

VViatris Specialty LLC

Approved

7 9

Inderal

WWyeth-Lederle Vaccines

Approved

5 10

Cymbalta

Jazz Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Post-Traumatic Stress Disorder

NCT06412757

Clinical

Trials by Indication[1]

Post-Traumatic Stress Disorder1 trial

Silexan in the Treatment Of Posttraumatic Stress Disorder Trial

Recruiting·—·Phase 3·NCT06412757·278 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Silexan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Silexan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Silexan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Deakin University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDeakin University

Silexan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Post-Traumatic Stress Disorder1 trial

References

Drug Info

Quick Facts

Related News